COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial...
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed...
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology...
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.